This site is supported by
(CDI) is a consequence of antibiotic use, which is exacerbated by inappropriate and widespread use of broad-spectrum agents. Any steps which can be implemented to effectively target narrow- spectrum antibiotic therapy would have a positive impact on the down-stream incidence of (CDI) as well as a substantial reduction of associated healthcare costs.
In addition, diagnostics for (CDI) are challenging. In recent times, traditional toxin A/B EIA tests have been identified as sub-optimal in performance and not recommended as single-line tests by various national guidelines.1,2,3,4,5
More recently, molecular-based tests have become commercially available but the latest data suggests these tests are not specific enough to be used as single-line tests.6 There are real concerns that these tests may overdiagnose (CDI), resulting in inappropriate antimicrobial therapy and an increased likelihood of a more severe re-infection.
- Crobach, et al. Clin Micro and Infect 2009
- Delmee, et al. J Med Micro 2005
- Planche, et al. Lancet Infect Dis 2008
- Eastwood, et al. J Clin Micro 2009
- Cohen, et al. Infect Control Hosp Epidemiol 2010
- U.K. Department of Health. Updated guidance on the diagnosis and reporting of C. difficile. 2012